About Ionetix
Ionetix is a company based in San Francisco (United States) founded in 2009. Ionetix has raised $61.08 million across 4 funding rounds from investors including Lilly and Tees River. Ionetix offers products and services including N-13 Ammonia and Targeted Alpha Therapy. Ionetix operates in a competitive market with competitors including ImaginAb, Conavi, AC Immune, APRINOIA and Innovate Biopharma, among others.
- Headquarter San Francisco, United States
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Ionetix Corporation
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$61.08 M (USD)
in 4 rounds
-
Latest Funding Round
Not available
-
Investors
Lilly
& 1 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Ionetix
Ionetix offers a comprehensive portfolio of products and services, including N-13 Ammonia and Targeted Alpha Therapy.
Radiopharmaceutical for cardiac PET imaging diagnostics.
Uses alpha radionuclides for targeted cancer therapy applications.
People of Ionetix
Unlock access to complete
Funding Insights of Ionetix
Ionetix has successfully raised a total of $61.08M across 4 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Ionetix
Ionetix has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Lilly and Tees River.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Traditional pharmaceutical medicines are developed for multiple health fields.
|
Locked | Locked | Locked | |
|
Invests in sustainable returns from global economy's Net Zero transition for professional investors.
|
Locked | Locked | Locked |
Investor details for Ionetix
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Ionetix
Investment portfolio details for Ionetix
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Ionetix
Detailed financials for Ionetix
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Ionetix Comparisons
Peer comparison for Ionetix
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Ionetix
Ionetix operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as ImaginAb, Conavi, AC Immune, APRINOIA and Innovate Biopharma, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
ImaginAb is focused on developing advanced immuno-oncology imaging technologies.
|
|
| Locked | Locked | Locked |
Catheter-based ultrasound systems for cardiac imaging are developed.
|
|
| Locked | Locked | Locked |
Antibodies, small molecules, and vaccines are developed for neurodegenerative diseases.
|
|
| Locked | Locked | Locked |
Diagnostics and therapeutics for neurodegenerative disorders are developed.
|
|
| Locked | Locked | Locked |
Small molecule drugs and imaging agent for GI disorders
|
|
| Locked | Locked | Locked |
Imaging compounds & targeted radiotherapies to detect and treat prostate cancer.
|
Detailed competitors of Ionetix
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Ionetix
Complete news archive for Ionetix
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Ionetix
Ionetix was founded in 2009 and raised its 1st funding round 9 years after it was founded.
Ionetix is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Kevin Cameron is the current CEO of Ionetix.
Ionetix is a funded company, having raised a total of $61.08M across 4 funding rounds to date.
Ionetix Corporation was founded in 2009 and is headquartered in San Francisco, United States. Operations focus on the development of superconducting cyclotrons designed for on-site production of positron emission tomography (PET) radioisotopes. The ION-12 system automates the generation of N-13 ammonia, an FDA-approved radiopharmaceutical utilized in myocardial perfusion PET studies to detect coronary artery disease. This technology is applied within the medical imaging sector.
Ionetix offers N-13 Ammonia and Targeted Alpha Therapy.
Ionetix has 2 investors. Key investors include Lilly, and Tees River.